All In Biotech

Drug Trial Radar · NCT06608641

Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients With Acute Mania Episodes With or Without Mixed Features

Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 490 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

490

Planned (sponsor's estimate)

Start

Mar 19, 2024

Primary completion

Jun 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Jina Pharmaceuticals Inc.Industry
Sponsor type
Industry
Collaborators
Novum Pharmaceutical Research Services
First posted
Sep 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability that affects the adult population. Endoxifen is an active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the Bipolar I disorder patient population compared to a placebo arm. Endoxifen will be compared to a placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products. Thus, Endoxifen will be compared to placebo to demonstrate that the test product is safe and active.

Conditions

  • Bipolar 1 Disorder

Interventions

  • Endoxifen enteric-coated tablet (8 mg)Drug

    Patients will continue treatment with their initial randomized medication for 3 weeks

  • Placebo TabletsDrug

    Patients will be treated with Endoxifen Placebo Tablets for 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy - mean change from baseline to Day 21 in the total YMRS scoreTime frame: 27 days

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Synexus

    Cerritos, California

  • NRC Research Institute

    Los Angeles, California

  • NRC Research Institute

    Orange, California

  • Medical Research of Westchester, Inc.

    Miami, Florida

  • Sunshine Medical Research Studies Inc.

    Miami, Florida

  • Innovative Clinical Research, Inc.

    Miami Lakes, Florida

  • South Florida Research Phase I-IV, Inc.

    Miami Springs, Florida

  • Santos Research Center, CORP

    Tampa, Florida

  • Accelerated Clinical Trials, LLC

    East Point, Georgia

  • Accelerated Clinical Trials, LLC

    Norcross, Georgia

  • Accelerated Clinical Trials, LLC

    Peachtree Corners, Georgia

  • Precise Research Centers

    Flowood, Mississippi

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.